0 items
CHECKOUT
 Latest News
 Quick Search
 Personal Profiles
 Current Events
 Industry News
 Managed Profiles
 Simple Search
 Advanced Search
 Recent Queries
 Companies By Industry
 Corporate Surveys
 Predecessor & Defunct
 Corporate Analyzer
 Investor Reports
 Historical Reports
 Industry Reports
 Dividends
 New Issues
 Mergers & Acquisitions
 Directory of Directors
 Additional Databases
 Person Search
 Global Search
 Lead List Generator
 Browse Radio
 Search Radio
 Browse Television
 Search Television
 Television Profiles
Company Snapshot

COMPANY INFORMATION
Helix BioPharma Corp.
3-305 Industrial Pky S
Aurora, ON
L4G 6X7
Tel: (905) 841-2300
Fax: (905) 841-2244

Contact Name
Photios Michalargias

Industry
Pharmaceuticals
 

Key Executives
Donald H. Segal, CEO
Photios Michalargias, CFO

Develops, licenses, markets and distributes bio-medical and pharmaceutical products and services. The company is principally focused on the development of two emerging drug products for the prevention and treatment of cancer: Topical Interferon Alpha-2b for the treatment of conditions caused by the human papilloma virus, and L-DOS47 drug candidate for the treatment of lung cancer. In addition, the company earns revenue from its drug distribution business in Canada and international licensing arrangements.
FP ADVISOR COVERAGE
Helix BioPharma Corp.
FP Corporate Analyzer
FP Directory of Directors
FP Corporate Surveys
FP Investor Reports
FP Predecessor & Defunct
Ordering FP Products
 
TOP INDUSTRY PLAYERS
Pharmaceuticals
Company NameRevenue ($000s) 
Biovail Corporation 807,909
Patheon Inc. 765,812
Cangene Corporation 238,751
Dragon Pharmaceutical, Inc. 162,127
Paladin Labs Inc. 82,744
(Links are to Snapshots.)
 
FINANCIAL RATIOS AS OF FEB 5/10
Listed Close 52-wk
High
52-wk
Low
IAD Latest
Dividend
Yield 60-mo
Beta
TSX/HBP $2.65 $3.28 $1.15 n.a. n.a. n.a. 0.04
Avg 20-day
Volume
P/E 12-mo
EPS
EPS
Date
1-yr
Return
3-yr
Return
5-yr
Return
Market
Cap. (000s)
7,080 n.a. $-0.28 Oct. 31/09 54.97% 13.97% -5.14% $158,471
 
ANNUAL FINANCIALS
Periods ended: 12m July 31/09 12m July 31/08 12m July 31/07
$000s $000s $000s
Operating revenue 3,841 3,591 3,424
Net income (14,102) (6,964) (7,674)
Total assets 19,319 21,666 14,273
$ $ $
Earnings per share* (0.27) (0.16) (0.22)
% % %
Return on equity (75.04) (41.88) (57.67)
 
* Common
 
TRAILING 12-MONTH VALUES
Periods ended: Oct. 31/09 Oct. 31/08
$000s $000s
Operating revenue 3,742 3,825
Net income (15,254) (7,641)
$ $
Earnings per share (0.28) (0.16)
 

COMPANY NEWS
Results for 'Helix BioPharma Corp.' from past 30 days:
No hits.


(Links are to articles.)


© 2006-2010 Canwest Digital Media, a division of Canwest Publishing Inc. All Rights Reserved. Copyright | Terms Of Use | Privacy Statement